FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080846895> ?p ?o ?g. }

• W2080846895 endingPage "211" @default.
• W2080846895 startingPage "211" @default.
• W2080846895 abstract "The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports David G Perahia,1 Mark E Bangs,2 Qi Zhang,2 Yingkai Cheng,2 Jonna Ahl,2 Elijah P Frakes,2 Michael J Adams,2 James M Martinez2 1Neurosciences, Lilly Research Centre, Windlesham, Surrey, UK; 2Neurosciences, Eli Lilly and Company, Indianapolis, IN, USA Purpose: To assess the safety of duloxetine with regards to bleeding-related events in patients who concomitantly did, versus did not, use nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin. Methods: Safety data from all placebo-controlled trials of duloxetine conducted between December 1993 and December 2010, and post-marketing reports from duloxetine-treated patients in the US Food and Drug Administration Adverse Event Reporting System (FAERS), were searched for bleeding-related treatment-emergent adverse events (TEAEs). The percentage of patients with bleeding-related TEAEs was summarized and compared between treatment groups in all the placebo-controlled studies. Differences between NSAID user and non-user subgroups from clinical trial data were analyzed by a logistic regression model that included therapy, NSAID use, and therapy-by-NSAID subgroup interaction. In addition, to determine if higher duloxetine doses are associated with an increased incidence of bleeding-related TEAEs, and whether the use of concomitant NSAIDs might influence the dose effect if one exists, placebo-controlled clinical trials with duloxetine fixed doses of 60 mg, 120 mg, and placebo were analyzed. Also, the incidence of bleeding-related TEAEs reported for duloxetine alone was compared with the incidence in patients treated with duloxetine and concomitant NSAIDs. Finally, the number of bleeding-related cases reported for duloxetine in the FAERS database was compared with the numbers reported for all other drugs. Results: Across duloxetine clinical trials, there was a significantly greater incidence of bleeding-related TEAEs in duloxetine- versus placebo-treated patients overall and also in those patients who did not take concomitant NSAIDS, but no significant difference was seen among those patients who did take concomitant NSAIDS. There was no significant difference in the incidence of bleeding-related TEAEs in the subset of patients treated with duloxetine 120 mg once daily versus those treated with 60 mg once daily regardless of concomitant NSAID use. The combination of duloxetine and NSAIDs was associated with a statistically significantly higher incidence of bleeding-related TEAEs compared with duloxetine alone. A similarly higher incidence of bleeding-related TEAEs was seen in patients treated with placebo and concomitant NSAIDs compared with placebo alone. Bleeding-related TEAEs reported in the FAERS database were disproportionally more frequent for duloxetine taken with NSAIDs compared with the full FAERS background, but there was no difference in the reporting of bleeding-related TEAEs when the cases reported for duloxetine taken with NSAIDs were compared against the cases reported for NSAIDs alone. Conclusion: Concomitant use of NSAIDs was associated with a higher incidence of bleeding-related TEAEs in clinical trials regardless of whether patients were taking duloxetine or placebo; bleeding-related TEAEs did not appear to increase along with duloxetine dose regardless of NSAID use. In spontaneously reported post-marketing data, the combination of duloxetine and NSAID use was not associated with an increased reporting of bleeding-related events when compared to NSAID use alone. Keywords: antidepressant, gastrointestinal bleeding, NSAID, aspirin" @default.
• W2080846895 created "2016-06-24" @default.
• W2080846895 creator A5016915571 @default.
• W2080846895 creator A5018026838 @default.
• W2080846895 creator A5021441919 @default.
• W2080846895 creator A5026984704 @default.
• W2080846895 creator A5029091280 @default.
• W2080846895 creator A5043151942 @default.
• W2080846895 creator A5050512906 @default.
• W2080846895 creator A5065649213 @default.
• W2080846895 date "2013-11-01" @default.
• W2080846895 modified "2023-10-03" @default.
• W2080846895 title "The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports" @default.
• W2080846895 cites W1512474915 @default.
• W2080846895 cites W168854692 @default.
• W2080846895 cites W1971393265 @default.
• W2080846895 cites W1973239436 @default.
• W2080846895 cites W1977698384 @default.
• W2080846895 cites W1981809734 @default.
• W2080846895 cites W1982721912 @default.
• W2080846895 cites W1984259090 @default.
• W2080846895 cites W1986578760 @default.
• W2080846895 cites W1990079987 @default.
• W2080846895 cites W1990296841 @default.
• W2080846895 cites W1991109757 @default.
• W2080846895 cites W1991480414 @default.
• W2080846895 cites W1991504406 @default.
• W2080846895 cites W2000769256 @default.
• W2080846895 cites W2002991969 @default.
• W2080846895 cites W2003363634 @default.
• W2080846895 cites W2006010099 @default.
• W2080846895 cites W2013138613 @default.
• W2080846895 cites W2018804866 @default.
• W2080846895 cites W2030144095 @default.
• W2080846895 cites W2031574357 @default.
• W2080846895 cites W2032433826 @default.
• W2080846895 cites W2038995778 @default.
• W2080846895 cites W2040179400 @default.
• W2080846895 cites W2043177024 @default.
• W2080846895 cites W2043595892 @default.
• W2080846895 cites W2045505967 @default.
• W2080846895 cites W2047902057 @default.
• W2080846895 cites W2048519309 @default.
• W2080846895 cites W2051675429 @default.
• W2080846895 cites W2059830154 @default.
• W2080846895 cites W2069090735 @default.
• W2080846895 cites W2069643552 @default.
• W2080846895 cites W2075103004 @default.
• W2080846895 cites W2076728061 @default.
• W2080846895 cites W2077180536 @default.
• W2080846895 cites W2081246082 @default.
• W2080846895 cites W2082632705 @default.
• W2080846895 cites W2083274218 @default.
• W2080846895 cites W2085752173 @default.
• W2080846895 cites W2086704277 @default.
• W2080846895 cites W2087490647 @default.
• W2080846895 cites W2092902579 @default.
• W2080846895 cites W2093196756 @default.
• W2080846895 cites W2101271922 @default.
• W2080846895 cites W2104688020 @default.
• W2080846895 cites W2105710387 @default.
• W2080846895 cites W2106059433 @default.
• W2080846895 cites W2106399435 @default.
• W2080846895 cites W2107255713 @default.
• W2080846895 cites W2115562984 @default.
• W2080846895 cites W2118984041 @default.
• W2080846895 cites W2124549431 @default.
• W2080846895 cites W2124733814 @default.
• W2080846895 cites W2128447164 @default.
• W2080846895 cites W2135432810 @default.
• W2080846895 cites W2150481636 @default.
• W2080846895 cites W2164863281 @default.
• W2080846895 cites W2171602968 @default.
• W2080846895 cites W2237974589 @default.
• W2080846895 cites W229326833 @default.
• W2080846895 cites W2313331832 @default.
• W2080846895 cites W2993596096 @default.
• W2080846895 cites W72273208 @default.
• W2080846895 doi "https://doi.org/10.2147/dhps.s45445" @default.
• W2080846895 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3849082" @default.
• W2080846895 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24348072" @default.
• W2080846895 hasPublicationYear "2013" @default.
• W2080846895 type Work @default.
• W2080846895 sameAs 2080846895 @default.
• W2080846895 citedByCount "7" @default.
• W2080846895 countsByYear W20808468952014 @default.
• W2080846895 countsByYear W20808468952015 @default.
• W2080846895 countsByYear W20808468952016 @default.
• W2080846895 countsByYear W20808468952017 @default.
• W2080846895 countsByYear W20808468952018 @default.
• W2080846895 countsByYear W20808468952021 @default.
• W2080846895 crossrefType "journal-article" @default.
• W2080846895 hasAuthorship W2080846895A5016915571 @default.
• W2080846895 hasAuthorship W2080846895A5018026838 @default.
• W2080846895 hasAuthorship W2080846895A5021441919 @default.
• W2080846895 hasAuthorship W2080846895A5026984704 @default.
• W2080846895 hasAuthorship W2080846895A5029091280 @default.
• W2080846895 hasAuthorship W2080846895A5043151942 @default.

• next